33 results about "Bladder cells" patented technology

An adaptive cushion apparatus for minimizing force concentrations on body parts of a person seated or lying on a chair or bed includes an overlay cushion having a plurality of individual air bladder cells, each having thereon a stretchable piezoresistive force sensor of novel design and construction. The apparatus includes an electro-pneumatic control system for inflating and deflating individual air bladder cells to pressures measured by a pressure transducer which tend to minimize force concentrations sensed by the force sensors. A force minimization method according to the invention includes varying the inflation pressure in a first air bladder cell while measuring the sum of the forces exerted on all air bladder cells, repressurizing the first cell to that pressure for which a minimum total force was obtained, repeating the cyclical variation in pressure and re-inflation to a minimum force-obtaining pressure for each of the remaining air bladder cells, and repeating the sequence for all air bladder cells until the force variations are minimized below a predetermined threshold value.

A soliton air mattress includes an array of air bladder cells that are individually inflatable to quiescent pressure levels which provide comfortable support for a human body, and a soliton wave generator including an air pressure-pulse generator controlled by a wave sequence generator for introducing into ordered sequences of air bladder cells a wave-like time sequence of air pressure pulses which vary quiescent pressure levels in the cells, the pressure wave resulting in a soliton traveling wave of body support force reduction which traverses surfaces of the air bladder cells, thus reducing normal forces exerted on a body and minimizing the occurrence rate of shear forces exerted on the body, thereby inhibiting formation of bedsores. The soliton wave patterns may optionally simulate water waves and/or rocking motions of a boat to produce relaxing effects.

The present invention provides methods for imaging and the treatment of cancer. In certain embodiments, a polyarginine (e.g., R11) may be used to selectively image prostate or bladder cells (e.g., a metastatic prostate cancer). In other embodiments, a DOC-2/DAB2 peptide, optionally conjugated to a cell permeable peptide (e.g., R11) may be used to treat a cancer, such as prostate cancer.

The invention discloses a methodology for the culture of bladder cell lines and organoids from human bladder, both non-cancerous as well as cancer tissue.

The invention provides regulatory constructs comprising intron 3 of the prostate specific membrane antigen gene (PSMA). An isolated nucleic acid molecule encoding the partial sequence of intron 3 of PSMA, a vector and a recombinant expression cassette are disclosed. The invention also provides a method of directing expression of a coding sequence in a prostate cell, a bladder cell, a breast cell and a vascular endothelial cell using the said constructs. This invention further provides a method of treatment of cancer using the said constructs.

A traveling wave air mattress apparatus includes an air mattress comprised of an array of laterally disposed, longitudinally spaced air bladder cells that are individually inflatable to quiescent pressure levels which provide comfortable support for a human body, and an air pressure-pulse generator controlled by a wave sequence generator for periodically introducing into sequences of the air bladder cells timed sequences of air pressure pulses which vary pressures in the cells from quiescent pressures, the air pressure variations resulting in leading and lagging soliton-like traveling waves of body support force variation which travel longitudinally over the surfaces of the pulsed air bladder cells, thus inhibiting formation of bedsores. The wave patterns may optionally simulate water waves and/or rocking motions of a boat to produce relaxing effects.

The invention refers to a novel molecular biomarker, namely PTPD1, that is markedly increased in human bladder cancers. PTPD1 expression positively correlated with the grading and invasiveness potential of these tumors. PTPD1 can be detected at high levels in exfoliated bladder cells isolated from urine of bladder cancer patients, while no PTPD1 signal was evident in normal exfoliated bladder cells. Thus, PTPD1 detection in urine samples may represent a novel and reliable marker for non-invasive diagnosis of aggressive bladder cancer.

The invention relates to a long non-coding RNA for diagnosis, treatment and monitoring on the bladder cancer and application of the RNA. Through a lncRNA expression chip, an expression profile of lncRNA in a sample of a patient with the bladder cancer is detected, more than ten kinds of the lncRNA closely related to generation and development of the bladder cancer are discovered through analysis,the lncRNA is subjected to knock-down inhibition in a bladder cell line T24 in sequence, the drug sensitivity of T24 cells to DDP after all lncRNA sequences are inhibited is analyzed, a lncKMU15 whichis not reported at home and abroad is discovered, after knock-down, the IC500 of the DDP is obviously reduced, and the sensibility is obviously improved; the expression amount discovered through experimental verification is in obvious positive correlation with staging and grading of the tumor and in negative correlation with the total survival rate and non-tumor survival rate of the patient withthe bladder cancer, and the novel lncRNA-KMU15 provides brand-new possibility for exploration of a novel noninvasive molecular diagnosis technology to achieve sensitive early screening on the bladdercancer and an after-operation monitoring system.

The invention discloses a sialyltransferase recombinant plasmid and application of the sialyltransferase recombinant plasmid and pemetrexed in the preparation of a medicament for inhibiting proliferation and invasion of bladder cancer. The growth and proliferation of bladder cancer cells can be effectively inhibited by constructing a plasmid overexpressing a sialyltransferase ST3Gal4 gene, and theplasmid plays a role in the growth and proliferation of bladder cancer cells by mediating a PI3K-AKT signaling pathway. Further, after cell transfection and with the combined effect with pemetrexed,the recombinant plasmid can further inhibit the ability of bladder cells to proliferate and migrate. The sialyltransferase ST3Gal4 can be used as an indicator of bladder cancer disease. Therefore, thetechnology of the present invention provides a good application prospect in preparing a medicament for inhibiting proliferation and invasion of bladder cancer, and provides a new target for early diagnosis and treatment of bladder cancer.

The present invention relates to compositions comprising therapeutic and/or diagnostic anionic agents together with cationic peptides and their use in methods for delivering the anionic agents to bladder cells.

The invention relates to an application of a D-xylose product to preparation of a UTI (urinary tract infection) preventing and treating drug. Cytobiologic experiments and animal experiments prove thatD-xylose can effectively prevent binding of UPEC (uropathogenic Escherichia coli) with bladder cells and nephrocytes, remarkably reduces colonization of UPEC in the urinary bladder of a mouse body and has the effect of preventing and treating UPEC derived UTI.

A method of detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises detecting an epigenetic change in at least one gene selected from FOXE1 and GATA4. Detection of the epigenetic change is indicative of a predisposition to, or the incidence of, bladder cancer. The sample comprises nucleic acid molecules from bladder cells. The methods may be used to select treatments and patients for treatment. Related kits include primers allowing the methylation status of the genes to be determined.

The invention discloses application of lobaplatin in preparation of a medicine for treating bladder cancer, belongs to the technical field of new applications of chemical medicines, and particularly relates to application of a platinum medicine in bladder cancer. The lobaplatin dosage form is a freeze-dried powder injection, a small-volume injection or a large-volume injection, and the effective treatment amount is 45-55 mg/m<2> body surface area. The lobaplatin and the lobaplatin preparation have the advantages of strong bladder cell tumor resistance, substantial treatment effect, low toxicity, safety, provision of a new treatment medicine for bladder cancer, and expansion of the clinical application of lobaplatin and the lobaplatin preparation.

The invention discloses compound oral liquid capable of treating cholecystitis and a preparation method thereof. The compound oral liquid mainly comprises taurocholic acid, serrapetase, oleanolic acid, ginkgo biloba extract, gallate, apigenin, folic acid, serine, vitamin C, stigmasterol, elsholtzia ketone, simple syrup, honey and distilled water, and further comprises the following auxiliary materials: a sweetening agent, a suspending agent, a wetting agent and a preservative. The compound oral liquid has relatively good antisepsis and anti-inflammation effects, a favorable gallbladder nourishing effect, a favorable pain relief effect and a favorable cholesterol secretion regulation effect, and is capable of dredging biliary ducts, promoting fat metabolism of muscle bodies, effectively improving the immunity of the muscle bodies, meanwhile enhancing the activity of gall bladder cells, and reducing cholesterol deposition so as to prevent gallstones; western and traditional Chinese medicines are effectively combined, so that the medical effect is mild and stable, untoward effect is avoided, and the compound oral liquid has a favorable clinical effect in prevention and treatment of the cholecystitis.

The invention provides methods, nucleic acids and kits for detecting bladder carcinoma. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients.

The invention discloses an in-situ primary bladder cancer tumor model preparation method, and belongs to the field of tumor animal models. According to the invention, normal bladder cells of mice are cultured into organoids with a specific culture medium, and then the organoids are subjected to gene editing and injected back to the bladder of the mice, so that the organoids are developed into tumors. Compared with a genetic engineering tumor animal model, the method disclosed by the invention is short in time consumption and high in tumor formation rate; compared with a transplanted tumor animal model, the model has an in-vivo microenvironment for tumor generation and development and a process from normal to tumor generation and development, and is closer to the most real state of bladder cancer generation and development.